查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1412856

肺癌基因組檢測市場：按技術、樣本類型、面板類型和最終用戶分類 - 2024-2030 年全球預測

Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction), Sample Type (Liquid Biopsy, Tissue Biopsy), Panel Type, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年肺癌基因組檢測市場規模為10.1億美元，預計2024年將達10.7億美元，2030年將達17.3億美元，複合年成長率為8.00%。

肺癌基因組檢測的全球市場

主要市場統計
基準年[2023] 10.1億美元
預測年份 [2024] 10.7億美元
預測年份 [2030] 17.3億美元
複合年成長率（%） 8%
肺癌基因組檢測市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估肺癌基因組檢測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對肺癌基因組檢測市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-肺癌基因組檢測市場的市場規模和預測是多少？

2-在肺癌基因組檢測市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-肺癌基因組檢測市場的技術趨勢和法律規範是什麼？

4-肺癌基因組檢測市場主要廠商的市場佔有率為何？

5-進入肺癌基因組檢測市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的癌症發生率正在增加
      • 政府努力擴大肺癌治療範圍
      • 加強研究力度和合作以擴大癌症治療和預防
    • 抑制因素
      • 基因檢測服務成本高且無法報銷
    • 機會
      • 下一代基因組定序的進展
      • 個人化醫療的趨勢和生物標記測試的引入
    • 任務
      • 關於基因和分子檢測的嚴格規定
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章肺癌基因組檢測市場：依技術分類

  • 螢光原位雜合反應
  • 下一代定序
  • 聚合酶鍊式反應

第7章依樣本類型分類的肺癌基因組檢測市場

  • 液體活體組織切片
  • 組織切片檢查

第8章按面板類型分類的肺癌基因組檢測市場

  • 多基因組合
  • 單基因組

第9章肺癌基因組檢測市場：依最終用戶分類

  • 診斷實驗室
  • 醫院/診所
  • 研究機構

第10章美洲肺癌基因組檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區肺癌基因組檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲肺癌基因組檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第14章競爭產品組合

  • 主要公司簡介
    • Abbott Laboratories
    • Admera Health
    • Agilent Technologies, Inc.
    • BGI
    • CD Genomics
    • CeGaT GmbH
    • Centogene NV
    • F. Hoffmann-La Roche AG
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • NeoGenomics Laboratories
    • OncoDNA
    • OPKO Health, Inc.
    • QIAGEN NV
    • Quest Diagnostics Incorporated
    • Thermo Fisher Scientific, Inc.
    • Veracyte, Inc.
  • 主要產品系列

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-7C31448F0BBE

[181 Pages Report] The Lung Cancer Genomic Testing Market size was estimated at USD 1.01 billion in 2023 and expected to reach USD 1.07 billion in 2024, at a CAGR 8.00% to reach USD 1.73 billion by 2030.

Global Lung Cancer Genomic Testing Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.07 billion
Forecast Year [2030] USD 1.73 billion
CAGR (%) 8%
Lung Cancer Genomic Testing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lung Cancer Genomic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lung Cancer Genomic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Genomic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Admera Health, Agilent Technologies, Inc., BGI, CD Genomics, CeGaT GmbH, Centogene N.V., F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, OncoDNA, OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Genomic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Fluorescence In Situ Hybridization
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Sample Type
    • Liquid Biopsy
    • Tissue Biopsy
  • Panel Type
    • Multi-Gene Panel
    • Single-Gene Panel
  • End User
    • Diagnostic Laboratories
    • Hospitals/Clinics
    • Research Organization
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lung Cancer Genomic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lung Cancer Genomic Testing Market?

3. What are the technology trends and regulatory frameworks in the Lung Cancer Genomic Testing Market?

4. What is the market share of the leading vendors in the Lung Cancer Genomic Testing Market?

5. Which modes and strategic moves are suitable for entering the Lung Cancer Genomic Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Lung Cancer Genomic Testing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of cancer incidences across the world
      • 5.1.1.2. Government initiatives to expand access to lung cancer treatment
      • 5.1.1.3. Growing number of research activities and collaborations to expand cancer care and prevention
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of genetic testing services and the lack of reimbursement
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in next-generation genome sequencing
      • 5.1.3.2. Inclination toward adoption of personalized medicine and biomarker testing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations concerning genetic and molecular testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Lung Cancer Genomic Testing Market, by Technology

  • 6.1. Introduction
  • 6.2. Fluorescence In Situ Hybridization
  • 6.3. Next-Generation Sequencing
  • 6.4. Polymerase Chain Reaction

7. Lung Cancer Genomic Testing Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Liquid Biopsy
  • 7.3. Tissue Biopsy

8. Lung Cancer Genomic Testing Market, by Panel Type

  • 8.1. Introduction
  • 8.2. Multi-Gene Panel
  • 8.3. Single-Gene Panel

9. Lung Cancer Genomic Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals/Clinics
  • 9.4. Research Organization

10. Americas Lung Cancer Genomic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lung Cancer Genomic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lung Cancer Genomic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Admera Health
    • 14.1.3. Agilent Technologies, Inc.
    • 14.1.4. BGI
    • 14.1.5. CD Genomics
    • 14.1.6. CeGaT GmbH
    • 14.1.7. Centogene N.V.
    • 14.1.8. F. Hoffmann-La Roche AG
    • 14.1.9. Illumina, Inc.
    • 14.1.10. Laboratory Corporation of America Holdings
    • 14.1.11. NeoGenomics Laboratories
    • 14.1.12. OncoDNA
    • 14.1.13. OPKO Health, Inc.
    • 14.1.14. QIAGEN N.V.
    • 14.1.15. Quest Diagnostics Incorporated
    • 14.1.16. Thermo Fisher Scientific, Inc.
    • 14.1.17. Veracyte, Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER GENOMIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. LUNG CANCER GENOMIC TESTING MARKET DYNAMICS
  • FIGURE 7. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 10. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2030 (%)
  • FIGURE 12. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MULTI-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SINGLE-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. LUNG CANCER GENOMIC TESTING MARKET SIZE, BY RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. LUNG CANCER GENOMIC TESTING MARKET LICENSE & PRICING